Patient-Derived Lung Cancer Organoid Model

The lungs are the primary organs of the respiratory system. They mainly participate in the process of gas exchange. Lung cancer is caused by genetic damage to the DNA of cells in the airways, often caused by cigarette smoking or inhaling damaging chemicals. Without treatment, tumors spread throughout the lung, damaging lung function and metastasizing to other body parts. So, enthusiasm for lung cancer drugs continues to grow. Creative Biolabs understands your lung cancer research needs and is your trustworthy partner for the mechanism research on lung cancer and the drug development of preclinical stages.

Overview

The generation of lung cancer organoids involves several critical operations. Firstly, surgically resect the tumor tissue sample from the patient’s lungs. Next, cut tumor tissues into small pieces, followed by gentle grinding and filtering. Finally, collect the suitable size of the tumor pieces and suspend them in an optimized culture well-designed medium for overnight culture. The prepared cultures can be applied in the subsequent long-term culture and the drug sensitivity test.

Fig 1. Generation of lung cancer organoids (LCOs) from lung tumor tissues.¹

Advantages of Patient-derived Lung Cancer Organoid Models

By contrast, recently developed patient-derived organoid (PDO) models make up for these defects of 2D cultures and patient-derived xenograft (PDX) models and are physiologically and clinically more advanced, providing an unparalleled strategy for studying lung cancer and creating an opportunity to tailor therapies for individual patients.

• Capture and retain the molecular, cellular, genetic, and histological phenotypes of the original tumor even better.
• Maintain patient-specific tumor heterogeneity.
• Show a short culture cycle and long-term in vitro expansion capability.

Applications

Such models that accurately recapitulate the biology of lung cancer are used for further investigation of biomarkers and drug screening. Some researchers have also constructed PDO biobanks and organoid models for use in drug trials, elucidation of the mechanisms of metastasis and resistance, the pathophysiology of tumorigenesis, and personalized medicine.

Fig.2 Applications of patient-derived lung cancer organoids. (Creative Biolabs)

Related Services

Creative Biolabs is committed to providing the highest quality patient-derived lung cancer organoid model and services to help your preclinical drug research project.

Why Choose Us?

• High-quality and customizable PDO models of various tissue sources are available to meet your specific needs.
• Professional histopathological confirmation and standard and customized clinical data ensure you receive the most suitable specimen.
• We are able to collect diseased biospecimens as well as normal human biospecimens ethically.
• Efficient response speed keeps your project on schedule.

Creative Biolabs is a global leader in providing 3D organoid models to researchers in the life sciences and pharmaceuticals. Don’t hesitate to contact us to discuss your project for professional assistance.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model